Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02GlobeNewsWire • 05/10/22
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11GlobeNewsWire • 04/29/22
Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage MelanomaBusiness Wire • 04/26/22
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/22/22
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02GlobeNewsWire • 03/07/22
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with MerckGlobeNewsWire • 01/26/22
Evaxion Biotech AS Sponsored ADR (EVAX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 01/25/22
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of MelanomaGlobeNewsWire • 01/18/22
Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 11/09/21
Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/21
Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional CapitalGlobeNewsWire • 10/26/21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with MelanomaGlobeNewsWire • 10/25/21
Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership AwardGlobeNewsWire • 10/14/21
Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021GlobeNewsWire • 10/12/21
Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/12/21
Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8GlobeNewsWire • 07/07/21
Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic ProgrammingGlobeNewsWire • 06/25/21